New: NCI-funded clinical trial search
Mednet Logo
SpecialtiesEndocrinology
Endocrinology

Endocrinology

Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.

Recent Discussions

Is there a role for monitoring PTH levels in patients with advanced chronic kidney disease who are receiving denosumab in order to assess for adynamic bone disease?

2
1 Answers

Mednet Member
Mednet Member
Nephrology · UCLA

It is more important to monitor PTH and bone-specific alkaline phosphatase prior to the initiation of denosumab. If PTH and bone-specific alkaline phosphatase are suggestive of adynamic bone disease, I would recommend a bone biopsy to rule out adynamic bone disease prior to the initiation of denosum...

Do you recommend restarting a GLP-1RA after bariatric surgery if the patient tolerated it before the surgery?

1
2 Answers

Mednet Member
Mednet Member
Hospital Medicine · Emory University Hospital

While there are no clear recommendations on whether/when to resume GLP-1 RA after bariatric surgery, current 2025 guideline statements (ASMBS, ADA, AACE, Obesity Society) and expert consensus documents suggest the following approach: Hold GLP-1RA in the acute perioperative period. For daily-dosed ...

Does oral Wegovy have a worse side effect profile compared to its injectable version?

2 Answers

Mednet Member
Mednet Member
Endocrinology · Brigham And Womens Hospital Endocrinology

From a clinical standpoint, I would say that oral semaglutide does cause more nausea and other GI side effects than injectable semaglutide for comparable doses. I am not aware of any randomized trials looking at this question, but there are single-center retrospective studies corroborating my impres...

Is the rise in LDL and liver fat after starting tryngolza a concern?

1 Answers

Mednet Member
Mednet Member
Endocrinology · Harvard Medical School

A modest increase in LDL-C after olezarsen (Tryngolza) and plozasiran (Redemplo) have been been reported, particularly in patients with severe hypertriglyceridemia. It probably reflects the conversion of TG-rich LPs and TG-remnants to smaller lipid particles, including IDL and LDL. Notably, the non-...

Do you manage mild-to-moderate diabetic ketoacidosis with a subcutaneous rapid-acting insulin protocol rather than an IV insulin infusion?

1 Answers

Mednet Member
Mednet Member
Endocrinology · Beth Israel Deaconess Medical Center

Yes, SC rapid-acting insulin can be used in the mild cases of DKA, provided that dehydration is not severe enough to affect insulin absorption. Small, frequent doses every hour may replace the IV insulin in mild cases. A good tip is to start correcting fluid loss in the first or two hours before sta...

What therapies do you offer patients who have osteoporosis and CKD and have had adverse reactions to several oral bisphosphonate therapies and denosumab?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Icahn School of Medicine at Mount Sinai

Without further details as to the severity of CKD, the severity of the osteoporosis, and the specific intolerance issues with denosumab (and/or BPs), this is a very difficult question to provide specific advice. Some general comments can be offered: CKD stage 4-5 is essentially without fracture data...

How do you decide when to treat hypocalcemia in hospitalized patients?

1 Answers

Mednet Member
Mednet Member
Hospital Medicine · UT Health San Antonio

When I think about when to treat hypocalcemia in hospitalized patients, I anchor the decision on three things: symptoms, the absolute calcium level, and the trajectory. First, it’s important to confirm true hypocalcemia: either a serum calcium <8 mg/dL or an ionized calcium <1.1 mmol/L, and to consi...

How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?

2
2 Answers

Mednet Member
Mednet Member
Endocrinology · Brigham And Womens Hospital Endocrinology

SGLT2-inhibitors have been known to precipitate episodes of diabetic ketoacidosis(DKA) with glucose levels far lower than are usually seen in DKA. This has been called euglycemic DKA. SGLT-2 inhibitors cause an increase in the glucagon to insulin ratio, which promotes ketosis, as well as fluid loss ...

How do you decide between adding oral orforglipron or starting prandial insulin in a patient with type 2 diabetes above goal on basal insulin?

1
1 Answers

Mednet Member
Mednet Member
Endocrinology · Texas Diabetes And Endocrinology Pa

This is a timely question in that it is clinically relevant, and in June 2026, the ACHIEVE-5 trial was published online in JAMA, which studied adding orforglipron to basal insulin.If the patient is judged to be significantly insulinopenic--thin, low dose of basal insulin requirement, and high postpr...

How has your approach to de-escalating a conversation with a distressed or angry family member evolved over your career?

1
1 Answers

Mednet Member
Mednet Member
Hospital Medicine · Icahn School of Medicine at Mount Sinai

My approach to de-escalating conversations with distressed or angry family members has shifted from trying to solve the problem immediately to first understanding the emotion driving the conflict. Early in my career, I often responded by providing more medical information, assuming that greater clar...